Your browser doesn't support javascript.
loading
Design, synthesis and biological evaluation of 2-pyrrolone derivatives as radioprotectors.
Satoh, Hidetoshi; Ochi, Shintaro; Mizuno, Kosuke; Saga, Yutaka; Ujita, Shohei; Toyoda, Miyu; Nishiyama, Yuichi; Tada, Kasumi; Matsushita, Yosuke; Deguchi, Yuichi; Suzuki, Keiji; Tanaka, Yoshimasa; Ueda, Hiroshi; Inaba, Toshiya; Hosoi, Yoshio; Morita, Akinori; Aoki, Shin.
Affiliation
  • Satoh H; Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.
  • Ochi S; Tokushima University, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan.
  • Mizuno K; Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.
  • Saga Y; Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.
  • Ujita S; Tokushima University, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan.
  • Toyoda M; Tokushima University, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan.
  • Nishiyama Y; Tokushima University, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan.
  • Tada K; Tokushima University, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan.
  • Matsushita Y; Tokushima University, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan; Department of Pharmacology and Therapeutic Innovation, Nagasaki University Graduate School of Biomedical Sciences, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan.
  • Deguchi Y; Center for Therapeutic Innovation, Nagasaki University Graduate School of Biomedical Sciences, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan.
  • Suzuki K; Department of Radiation Medical Sciences, Nagasaki University Atomic Bomb Disease Institute. 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.
  • Tanaka Y; Center for Medical Innovation, Nagasaki University, 1-7-1 Sakamoto, Nagasaki 852-8588, Japan.
  • Ueda H; Department of Pharmacology and Therapeutic Innovation, Nagasaki University Graduate School of Biomedical Sciences, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan.
  • Inaba T; Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan.
  • Hosoi Y; Department of Radiation Biology, Graduate School of Medicine, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
  • Morita A; Tokushima University, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan.
  • Aoki S; Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan; Research Institute for Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan; Research Institute for Biomedical Science, Tokyo University of Science,
Bioorg Med Chem ; 67: 116764, 2022 08 01.
Article de En | MEDLINE | ID: mdl-35635928
ABSTRACT
It is known that p53 is an important transcription factor and plays a central role in ionizing radiation (IR)-induced DNA damage responses such as cell cycle arrest, DNA repair and apoptosis. We previously reported that regulating p53 protein is an effective strategy for modulating cell fate by reducing the acute side effects of radiation therapy. Herein, we report on the discovery of STK160830 as a new radioprotector from a chemical library at The University of Tokyo and the design, synthesis and biological evaluation of its derivatives. The radioprotective activity of STK160830 itself and its derivatives that were synthesized in this work was evaluated using a leukemia cell line, MOLT-4 cells as a model of normal cells that express the p53 protein in a structure-activity relationships (SAR) study. The experimental results suggest that a direct relationship exists between the inhibitory effect of these STK160830 derivatives on the expression level of p53 and their radioprotective activity and that the suppression of p53 by STK160830 derivatives contribute to protecting MOLT-4 cells from apoptosis that is induced by exposure to radiation.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Protéine p53 suppresseur de tumeur / Apoptose Type d'étude: Prognostic_studies Langue: En Journal: Bioorg Med Chem Sujet du journal: BIOQUIMICA / QUIMICA Année: 2022 Type de document: Article Pays d'affiliation: Japon

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Protéine p53 suppresseur de tumeur / Apoptose Type d'étude: Prognostic_studies Langue: En Journal: Bioorg Med Chem Sujet du journal: BIOQUIMICA / QUIMICA Année: 2022 Type de document: Article Pays d'affiliation: Japon